← back to search

Shinichi Oka

AIDS United · US
Area of research
Infectious Diseases · Virology
Research interest
Research interests include HIV Research and Treatment, HIV/AIDS drug development and treatment, HIV/AIDS Research and Interventions, and HIV-related health complications and treatments.
h-index
58
citations
14,613
works
696
NIH funding
primary concept
Medicine
email

Recent publications

High plasma concentration of tenofovir alafenamide in people living with HIV with ABCB1 genetic variants.
2025cited by 1position: contributordoi
Month 12 outcomes of switching to long-acting cabotegravir + rilpivirine with an oral lead-in versus continuing bictegravir/emtricitabine/tenofovir alafenamide in the Phase 3b randomized SOLAR study.
2025cited by 0position: contributordoi
Determination of intracellular tenofovir-diphosphate and emtricitabine-triphosphate concentrations in dried blood spots for pre-exposure prophylaxis adherence.
2024cited by 2position: contributordoi
Effect of tenofovir-based HIV pre-exposure prophylaxis against HBV infection in men who have sex with men.
2023cited by 21position: contributordoi
Efficacy and Safety of Pre-Exposure Prophylaxis to Control HIV and Sexually Transmitted Infection Among Men Who Have Sex With Men: Protocol for a Single-Arm Interventional Study.
2023cited by 1position: contributordoi
Reply: Effect of tenofovir-based HIV pre-exposure prophylaxis against HBV infection in men who have sex with men.
2023cited by 0position: contributordoi
Sitafloxacin- Versus Moxifloxacin-Based Sequential Treatment for Mycoplasma Genitalium Infections: Protocol for a Multicenter, Open-Label Randomized Controlled Trial.
2023cited by 0position: contributordoi
Efficacy and Safety of Pre-Exposure Prophylaxis to Control HIV and Sexually Transmitted Infection Among Men Who Have Sex With Men: Protocol for a Single-Arm Interventional Study (Preprint)
2023cited by 0position: contributordoi
Sitafloxacin- Versus Moxifloxacin-Based Sequential Treatment for Mycoplasma Genitalium Infections: Protocol for a Multicenter, Open-Label Randomized Controlled Trial (Preprint)
2023cited by 0position: contributordoi
Metagenomic Identification of Microbial Signatures Predicting Pancreatic Cancer From a Multinational Study
Gastroenterology 2022cited by 211position: middledoi
A four-year observation of HIV and sexually transmitted infections among men who have sex with men before and during pre-exposure prophylaxis in Tokyo.
2022cited by 11position: contributordoi
Identification of asymptomatic Entamoeba histolytica infection by a serological screening test: A cross-sectional study of an HIV-negative men who have sex with men cohort in Japan.
2022cited by 9position: contributordoi
Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection
New England Journal of Medicine 2020cited by 454position: middledoi
Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials
JAIDS Journal of Acquired Immune Deficiency Syndromes 2020cited by 146position: middledoi
Review on the molecular epidemiology of sexually acquired hepatitis C virus infection in the Asia-Pacific region.
2020cited by 11position: contributordoi
CCR5AS lncRNA variation differentially regulates CCR5, influencing HIV disease outcome
Nature Immunology 2019cited by 101position: middledoi
CCR5AS lncRNA variation differentially regulates CCR5, influencing HIV disease outcome.
2019cited by 78position: contributordoi
Combination of Clindamycin and Azithromycin as Alternative Treatment for Toxoplasma gondii Encephalitis.
2019cited by 17position: contributordoi
Short Communication: A Quantitative System for Monitoring Blood-Circulating Viral Protein R of Human Immunodeficiency Virus-1 Detected a Possible Link with Pathogenic Indices.
2019cited by 9position: contributordoi
Full-Genome Analysis of Hepatitis C Virus in Japanese and Non-Japanese Patients Coinfected With HIV-1 in Tokyo.
2019cited by 8position: contributordoi
Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials
The Lancet 2015cited by 596position: middledoi
P99 Renal and bone safety of tenofovir alafenamide vs tenofovir disoproxil fumarate
Sexually Transmitted Infections 2015cited by 5position: middledoi
A genome-wide association study of resistance to HIV infection in highly exposed uninfected individuals with hemophilia A
Human Molecular Genetics 2013cited by 42position: middledoi
Assessment, Diagnosis, and Treatment of HIV-Associated Neurocognitive Disorder: A Consensus Report of the Mind Exchange Program
Clinical Infectious Diseases 2012cited by 207position: middledoi
Differential Clade-Specific HLA-B*3501 Association with HIV-1 Disease Outcome Is Linked to Immunogenicity of a Single Gag Epitope
Journal of Virology 2012cited by 55position: middledoi
HLA-associated viral polymorphism in chronically HIV-1-infected Japanese cohort: analysis of four-digit HLA allele level
Retrovirology 2012cited by 1position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

· 12 papers (2020–2025)Daisuke Mizushima · Elsevier, Inc.7 papers (2023–2024)Misao Takano · National Center for Global Health and Medicine6 papers (2022–2023)Hiroyuki Gatanaga · Kumamoto Health Science University4 papers (2023–2023)Koji Watanabe · Springer Nature4 papers (2022–2023)Naokatsu Ando · Elsevier, Inc.3 papers (2023–2023)Takahiro Aoki · National Center for Global Health and Medicine3 papers (2023–2023)Huyen Cao · Public Health Dayton & Montgomery County2 papers (2015–2015)Takato Nakamoto · Springer Nature2 papers (2023–2023) · 2 papers (2023–2023)Morika Mitobe · Tokyo Metropolitan Institute of Public Health2 papers (2023–2023)Haruka Uemura · Elsevier, Inc.2 papers (2020–2023)Yukari Uemura · Kobe University2 papers (2023–2023)Daisuke Tokita · National Center for Global Health and Medicine2 papers (2023–2023)Hiroaki Kubota · Waseda University2 papers (2023–2023)Kiyoto Tsuchiya · Japan Agency for Medical Research and Development2 papers (2024–2025)Yosuke Shimizu · Center for Global Health2 papers (2023–2023) · 2 papers (2023–2023)Hirofumi Miyake · Tokyo Metropolitan Institute of Public Health2 papers (2023–2023)Kai Kobayashi · Tokyo Metropolitan Institute of Public Health2 papers (2023–2023)